Responses
Therapeutics
Original research
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
Compose a Response to This Article
Other responses
No responses have been published for this article.